[1] Chen J, Xu Z, Hu C, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Front Oncol. 2023;13:1132319. Published 2023 Mar 10. doi:10.3389/fonc.2023.1132319
[2] 于鹏程,袁莉,胡灿,吴越,徐志远,程向东.CLDN18在消化系统肿瘤中表达的意义及现状研究进展[J].肿瘤学杂志,2021,27(10):798-804.DOI:10.11735/j.issn.1671-170X.2021.10.B002.
[3] Singh P., Toom S., Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J. Hematol. Oncol. 2017;10:105. doi: 10.1186/s13045-017-0473-4
[4] Jiang J; Si M; Luo X, et al., Abstract 5551: QLS31905, an anti-claudin 18.2/CD3 bispecific antibody for claudin 18.2-positive gastric cancer. Cancer Res (2022) 82 (12_Supplement): 5551.
https://doi.org/10.1158/1538-7445.AM2022-5551
[5] Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189-1198. doi:10.1038/s41591-022-01800-8
[6] Vonniessen B, Tabariès S, Siegel PM. Antibody-mediated targeting of Claudins in cancer. Front Oncol. 2024;14:1320766. Published 2024 Feb 2. doi:10.3389/fonc.2024.13207
